Traditional chemotherapy regimens served as the standard for years in uterine cancer, offering meaningful but often limited response rates for patients with advanced or recurrent disease. The options felt fixed, and for many patients, they were.
Then came a rapid series of pivotal shifts. FDA approvals in 2023 formally established combination regimens, pairing chemotherapy with immunotherapy, as a new frontline standard for advanced endometrial cancer. Based on data from the landmark RUBY trial and related studies, immunotherapy is now being moved into first-line treatment alongside chemotherapy. Drugs like pembrolizumab and dostarlimab, used in combination with standard chemotherapy, demonstrated significantly improved outcomes for eligible patients compared to chemotherapy alone.
What this means practically is that “chemo plus immunotherapy” is no longer an experimental idea. It’s a validated standard of care for many patients. But it isn’t automatic. You need to proactively ask your care team about these combinations at diagnosis, before a treatment plan is finalized. The eligibility for specific regimens depends heavily on your tumor’s biology, which is exactly why understanding your biomarker profile is the critical next step.
Biomarkers: The key to unlocking your treatment path
Your biomarker profile is now the single most important factor in determining which uterine cancer treatments are available to you. Biomarker testing for microsatellite instability (MSI), mismatch repair deficiency (dMMR), and HER2 status can help guide treatment decisions in advanced endometrial cancer and may help patients access targeted therapies and immunotherapies that are most likely to work for their specific cancer. That’s not a formality. It’s the gateway to a personalized care plan.
dMMR and MSI-H refer to the same underlying problem, just measured differently. Mismatch Repair Deficient (dMMR) means the cells have lost the proteins that normally correct DNA copying errors. Microsatellite Instability-High (MSI-H) is the measurable result of that breakdown, a pattern of genetic instability that makes tumors highly visible to the immune system. Patients with dMMR/MSI-H tumors tend to respond strongly to immunotherapy, which is why this result changes everything about the treatment conversation.
The dMMR vs. pMMR distinction is where your treatment path diverges sharply. Proficient Mismatch Repair (pMMR) tumors are less responsive to immunotherapy alone, and people with advanced or recurrent endometrial cancer with pMMR tumors may benefit from combination treatment approaches such as chemotherapy plus immunotherapy or targeted therapy plus immunotherapy. Patients in this category typically need combination approaches, a reality the next section addresses in depth.
HER2 status deserves equal attention, particularly for patients with uterine serous carcinoma. Once considered relevant only in breast cancer, HER2 overexpression is now a recognized driver in a subset of uterine cancers, opening access to targeted therapies that weren’t previously an option. Antibody-drug conjugates represent one promising area emerging from this HER2 research.
The Outcomes4Me app can help you organize these genetic results, flag what each biomarker means for your options, and bring informed questions to your care team, turning a lab report into a starting point for informed decisions.
Biomarker cheat sheet
Biomarker What it means Why it matters dMMR / MSI-H DNA repair proteins are missing or non-functional Strong predictor of immunotherapy response pMMR / MSS DNA repair system is intact Immunotherapy alone is less effective; combination therapy likely needed HER2+ Tumor overexpresses the HER2 protein Opens access to HER2-targeted therapies, especially in serous carcinoma
Immunotherapy breakthroughs: Dostarlimab and pembrolizumab
Immunotherapy has fundamentally reshaped what’s possible in advanced uterine cancer, and two drugs are leading that shift.
Dostarlimab (Jemperli) has become a cornerstone of dMMR endometrial cancer treatment, showing that checkpoint inhibitors can dramatically extend the time before a tumor progresses. By blocking the PD-1 pathway, dostarlimab essentially lifts the brakes cancer cells use to hide from your immune system. For patients whose tumors carry mismatch repair deficiency (dMMR), the results from the RUBY trial were striking. Adding dostarlimab to standard platinum-based chemotherapy produced a significant improvement in progression-free survival compared to chemo alone, a finding that helped accelerate FDA approval and reshape first-line treatment guidelines.
Pembrolizumab (Keytruda) combined with chemotherapy is being studied in patients with both dMMR and pMMR uterine cancers, with some research suggesting potential benefit, particularly in those with dMMR status. Your care team can discuss whether this approach may be appropriate for your individual situation. Progression-free survival, meaning the length of time a patient lives without their disease worsening, improved meaningfully, and for many patients, that translates directly into more quality time. The clinical evidence supporting pembrolizumab continues to grow with each updated analysis.
But what about pMMR patients who don’t respond as well to immunotherapy alone? That’s where the lenvatinib + pembrolizumab combination fills a critical gap. Lenvatinib is a targeted therapy that disrupts tumor blood supply, and when paired with pembrolizumab, it can re-sensitize tumors that would otherwise resist checkpoint blockade. It’s an important option to discuss with your care team if your biomarker profile places you in the pMMR category.
Immunotherapy is only part of the evolving treatment picture, though. Beyond these checkpoint inhibitors, a new wave of targeted therapies, including antibody-drug conjugates, is opening additional doors for patients whose tumors express specific markers.
The rise of ADCs and targeted therapy
Targeted therapy for uterine cancer has moved well beyond immunotherapy alone, and for patients whose tumors don’t respond to checkpoint inhibitors, a new generation of precision treatments is changing what’s possible.
Antibody-drug conjugates (ADCs) are arguably the most exciting frontier in uterine cancer research right now. Think of them as a “Trojan horse”. An antibody that seeks out a specific protein on cancer cells and delivers a potent chemotherapy payload directly to them, sparing much of the surrounding healthy tissue. For uterine cancer specifically, trastuzumab deruxtecan (Enhertu) is an option for patients with HER2-expressing tumors, particularly serous endometrial carcinoma. Trastuzumab (Herceptin) is already used for HER2-overexpressing serous endometrial carcinoma, and the ADC form takes that targeting principle further.
Beyond HER2, mutations in the PI3K/AKT/mTOR signaling pathway are among the most common in endometrial cancer. Targeted agents designed to block this pathway, such as mTOR inhibitors, offer another route for patients whose tumors carry these specific alterations, underlining why comprehensive biomarker testing matters so much.
For patients with low-grade, hormone receptor-positive disease, aromatase inhibitors represent a well-established but continuously refined strategy, sometimes called Hormone Therapy 2.0. These agents reduce estrogen levels that can fuel tumor growth, offering a lower-intensity option for carefully selected patients.
Navigating side effects and the ‘immune’ response
Understanding how immunotherapy side effects differ from chemotherapy is essential for anyone starting a new treatment regimen, and that difference shapes how you and your care team respond.
Immune-related adverse events (irAEs) are not the same as chemotherapy toxicity. Immunotherapy activates your immune system, which means side effects reflect an overactive immune response, not cell damage. Common reactions include fatigue, nausea, and skin rash, but more serious events, such as inflammation of the lungs (pneumonitis) or colon (colitis), require immediate intervention. HER2-positive uterine cancer can be treated with different targeted agents, and each of these drugs carries its own distinct side effect profile that patients should discuss with their doctor.
Early reporting is everything. A seemingly minor rash or new cough can escalate quickly if left unaddressed. That’s why prompt communication with your care team, through secure messaging or patient portals, isn’t just convenient. It’s clinically important. Your care team can distinguish between manageable inflammation and a signal that treatment needs to pause or change.
One important nuance. Experiencing side effects doesn’t mean the drug isn’t working, and the absence of side effects doesn’t mean it isn’t. In practice, the relationship between irAEs and treatment efficacy is complex. Some patients have robust responses with minimal side effects. Knowing this can help ease anxiety when you’re trying to interpret what your body is telling you, and points to the value of staying in close, ongoing conversation with your oncologist.
5 things to ask your oncologist today
Empowered patients who understand their molecular profile are better equipped to navigate the rapidly changing landscape of uterine cancer care, and that starts with asking the right questions at your next appointment.
The treatments available today look very different from those offered even three years ago. Knowing your tumor’s biomarker status isn’t a formality. It’s the foundation of your personalized care plan. As dostarlimab and pembrolizumab updates continue to reshape frontline treatment standards, patients who’ve confirmed their dMMR or MSI-H status are the ones most likely to benefit from these advances. If your care team hasn’t yet ordered comprehensive biomarker testing, that’s the first conversation to have.
Here are five specific questions worth raising:
- “Has my tumor been tested for dMMR, MSI, and HER2?” Comprehensive testing covers all three markers and shapes every treatment decision that follows.
- “Am I a candidate for adding immunotherapy to my frontline treatment?” Options like pembrolizumab are now approved in combination with chemotherapy for eligible patients.
- “What options exist if I’m pMMR?” Combination therapies and clinical trials are actively expanding for this group, so don’t assume fewer options means no options.
- “Are there ADC trials open for my subtype?” Antibody-drug conjugates are being studied in clinical trials for advanced uterine cancer and other solid tumors.
- “How can digital tools help me stay on top of new trials?” The Outcomes4Me app can match you with relevant trials in real time, so you’re never relying solely on a single conversation to know what’s available.
You are your own best advocate, and in a field where biomarker-driven treatment decisions are evolving as rapidly as uterine cancer care, that principle has never mattered more.
That’s exactly where the Outcomes4Me app steps in. Download the app today for personalized resources, symptom tracking, and community.
Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.
